These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1782074)

  • 1. Phase I study of DABIS maleate given once every 3 weeks.
    van der Burg ME; Planting AS; Stoter G; McDaniel C; Vecht CJ; Verweij J
    Eur J Cancer; 1991; 27(12):1635-7. PubMed ID: 1782074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent administration of Dabis Maleate, a phase I study.
    Verweij J; Planting AS; de Boer M; van der Burg ME; Stoter G
    Ann Oncol; 1992 Mar; 3(3):241-2. PubMed ID: 1586625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate).
    Broggini M; Hartley JA; Mattes WB; Ponti M; Kohn KW; D'Incalci M
    Br J Cancer; 1990 Feb; 61(2):285-9. PubMed ID: 2393411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX.
    Tagliabue G; Filippeschi S; Hendricks H; D'Incalci M
    Ann Oncol; 1992 Mar; 3(3):233-6. PubMed ID: 1586622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
    Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM
    Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
    Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
    Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.
    Schnaper HW
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S128-30. PubMed ID: 1725021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks.
    Creaven PJ; Cowens JW; Huben R; Petrelli N; Karakousis C; Traynor D
    Cancer Chemother Pharmacol; 1989; 23(4):266-7. PubMed ID: 2924383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-ranging trial of zacopride: the emetic antiemetic?
    Pisters KM; Kris MG; Tyson LB; Clark RA; Gralla RJ
    J Natl Cancer Inst; 1992 May; 84(9):717-8. PubMed ID: 1569606
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
    Capdevila J; Clive S; Casado E; Michie C; Piera A; Sicart E; Carreras MJ; Coronado C; Kahatt C; Soto Matos-Pita A; Fernandez Teruel C; Siguero M; Cullell-Young M; Tabernero J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1247-54. PubMed ID: 23455428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
    Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
    Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].
    Ota K; Wakui A; Majima H; Niitani H; Inuyama Y; Ogawa M; Ariyoshi Y; Yoshida O; Taguchi T; Kimura I
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):855-61. PubMed ID: 1605663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
    Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of metoprine in patients with advanced cancer.
    Currie VE; Kempin SJ; Young CW
    Cancer Treat Rep; 1980; 64(8-9):951-6. PubMed ID: 6969632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
    Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
    Awada A; Thödtmann R; Piccart MJ; Wanders J; Schrijvers AH; Von Broen IM; Hanauske AR;
    Eur J Cancer; 2003 Apr; 39(6):742-7. PubMed ID: 12651198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.